- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04057131
FIRAZYR General Drug Use-Results Survey (Japan)
March 27, 2024 updated by: Shire
The objectives of this survey are to collect data to report the safety and efficacy of Firazyr (Icatibant acetate) in the post-marketing phase in participants diagnosed with Hereditary Angioedema (HAE).
Study Overview
Detailed Description
FIRAZYR General Drug Use-Results Survey (Japan)
Study Type
Observational
Enrollment (Actual)
304
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Niigata, Japan, 950-1197
- Niigata-city
-
-
Aichi
-
Nagoya, Aichi, Japan, 453-0046
- Nagoya-city
-
Toyohashi, Aichi, Japan, 441-8570
- Toyohashi-city
-
-
Gunma
-
Maebashi, Gunma, Japan, 371-8511
- Maebashi-city
-
-
Hokkaido
-
Asahikawa, Hokkaido, Japan, 070-0034
- Asahikawa-city
-
Fukagawa, Hokkaido, Japan, 074-0006
- Fukagawa-city
-
Rumoi, Hokkaido, Japan, 077-0011
- Rumoi-city
-
Sapporo, Hokkaido, Japan, 002-8072
- Sapporo-city
-
-
Ibaraki
-
Kasama, Ibaraki, Japan, 309-1703
- Kasama-city
-
-
Kyoto
-
Maizuru, Kyoto, Japan, 625-8585
- Maizuru-city
-
-
Osaka
-
Kishiwada, Osaka, Japan, 596-0042
- Kishiwada-city
-
Takatsuki, Osaka, Japan, 569-0096
- Takatsuki-city
-
-
Saitama
-
Kawagoe, Saitama, Japan, 350-8550
- Kawagoe-city
-
Soka, Saitama, Japan, 340-0041
- Soka-city
-
-
Shizuoka
-
Numazu, Shizuoka, Japan, 410-0302
- Numazu-city
-
Shimada, Shizuoka, Japan, 427-8502
- Shimada-city
-
Yaezu, Shizuoka, Japan, 425-0088
- Yaezu-city
-
-
Tokyo
-
Tachikawa, Tokyo, Japan, 190-0014
- Tachikawa-city
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Hereditary angioedema (HAE) patients in Japan who receive FIRAZYR for first time in the real world clinical setting are eligible for enrollment in this survey.
Description
Inclusion Criteria:
- Hereditary angioedema (HAE) participants in Japan who receive FIRAZYR for first time in the real world clinical setting.
Exclusion Criteria
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Firazyr
Participants with Hereditary angioedema (HAE) receiving treatment with Icatibant acetate (Firazyr) as prescribed by their physician following locally approved prescribing information.
|
Participants with Hereditary angioedema (HAE) receiving treatment with Icatibant acetate (Firazyr) as prescribed by their physician following locally approved prescribing information.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Adverse Drug Reactions
Time Frame: 4 Years
|
Number of participants with adverse drug reactions will be assessed.
|
4 Years
|
Time to Treatment for Attack
Time Frame: 3 Months
|
Time to treatment for attack defined as the time between the onset of the attack and the first injection of treatment.
Time to treatment for attack will be assessed.
|
3 Months
|
Time to First Symptom Relief
Time Frame: 3 Months
|
Time to first symptom relief will be assessed.
|
3 Months
|
Time to Complete Resolution of Attack
Time Frame: 3 Months
|
Time to complete resolution of attack defined as the time between the first injection of treatment and the complete resolution of all symptoms.
Time to complete resolution of attack will be assessed.
|
3 Months
|
Total Duration of Attack
Time Frame: 3 Months
|
Total duration of attack defined as the time between the onset of the attack and the complete resolution of all symptoms.
Total duration of attack will be assessed.
|
3 Months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 9, 2019
Primary Completion (Actual)
March 22, 2024
Study Completion (Actual)
March 22, 2024
Study Registration Dates
First Submitted
August 13, 2019
First Submitted That Met QC Criteria
August 13, 2019
First Posted (Actual)
August 15, 2019
Study Record Updates
Last Update Posted (Actual)
March 28, 2024
Last Update Submitted That Met QC Criteria
March 27, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Skin Diseases
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Hypersensitivity, Immediate
- Genetic Diseases, Inborn
- Skin Diseases, Vascular
- Hypersensitivity
- Urticaria
- Hereditary Complement Deficiency Diseases
- Primary Immunodeficiency Diseases
- Angioedema
- Angioedemas, Hereditary
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Complement Inactivating Agents
- Bradykinin B2 Receptor Antagonists
- Bradykinin Receptor Antagonists
- Icatibant
Other Study ID Numbers
- SHP667-401
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5).
These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD Sharing Access Criteria
IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/.
For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hereditary Angioedema (HAE)
-
CENTOGENE GmbH RostockCompletedHereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | C1 Esterase Inhibitor Deficiency | HAE | Angio Edema | C4 Deficiency | Hereditary Angioedema Type IIITurkey, Armenia, Georgia, India, Peru, Poland, Romania
-
TakedaNot yet recruitingHereditary Angioedema (HAE)
-
CSL BehringRecruitingHereditary Angioedema (HAE)United States, Israel
-
TakedaRecruitingHereditary Angioedema (HAE)United Kingdom
-
TakedaRecruitingHereditary Angioedema (HAE)Japan
-
TakedaRecruitingHereditary Angioedema (HAE)Poland
-
ShireTakeda Development Center Americas, Inc.RecruitingHereditary Angioedema (HAE)France, Austria, Australia, Spain, Czechia, Italy, United Kingdom, Germany, Israel, Ireland, Brazil, Denmark, Greece, Sweden
-
ShireTakeda Development Center Americas, Inc.CompletedHereditary Angioedema (HAE)Canada, United States, Puerto Rico
-
TakedaCompletedHereditary Angioedema (HAE)France, Germany, Austria, Greece
-
ShireCompletedHereditary Angioedema (HAE)United States, Jordan, Canada
Clinical Trials on Firazyr
-
ShireCompletedHereditary AngioedemaUnited States, Australia, Israel, Canada, Hungary, Romania, Russian Federation, South Africa, Ukraine
-
ShireCompletedHereditary Angioedema (HAE)United States, Canada, Australia, Austria, Colombia, Germany, Hungary, Israel, Italy, Spain
-
ShireJerini AGCompletedHereditary AngioedemaSpain, Argentina, Austria, Denmark, France, Germany, Israel, Italy, Switzerland, United Kingdom
-
Massachusetts General HospitalShire Human Genetic Therapies, Inc.CompletedHereditary AngioedemaUnited States
-
ShirePPDCompletedAngiotensin Converting Enzyme Inhibitor Induced AngioedemaUnited States, Canada, United Kingdom, Israel
-
TakedaRecruitingHereditary Angioedema (HAE)Japan
-
ShireCompletedHereditary Angioedema (HAE)United States
-
Vanderbilt University Medical CenterShireTerminatedACE Inhibitor-associated AngioedemaUnited States
-
Sebastian VidelaCompleted
-
ShireCompletedAngioedemaUnited States